INM · InMed Pharmaceuticals Inc.

NasdaqHealthcareDrug Manufacturers - Specialty & Generic

Inmed Pharmaceuticals Inc Is A Pharmaceutical Company Developing A Pipeline Of Disease-Modifying Small Molecule Drug Candidates Targeting Cb1 And Cb2 Receptors. The Company'S Pipeline Consists Of Three Separate Programs In The Treatment Of Alzheimer'S, Ocular And Dermatological Indications.

HealthcareNasdaqCAVery Low Float

$5.50

+123.6% latest move

Price & move as of the most recent catalyst (Jun 23) — not a live quote.

FLOAT

3.3M

FREE FLOAT %

60%

SHARES O/S

5.5M

MARKET CAP

$7.5M

EXCHANGE

Nasdaq

COUNTRY

INM Catalyst History

Regulatory and ClinicalJun 23, 2025 · 7:59pm ET

INMInMed Pharmaceuticals Inc. Common Shares

InMed Pharmaceuticals Announces Preclinical Data for INM-901

Company reports significant reduction in neuroinflammation in Alzheimer's disease.

Be early on the next INM spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

INM · InMed Pharmaceuticals Inc.

INM Catalyst History

InMed Pharmaceuticals Announces Preclinical Data for INM-901

InMed Pharmaceuticals Announces Preclinical Data for INM-901

InMed Pharmaceuticals Announces Preclinical Success of INM-901 in Reducing Alzheimer's-Related Inflammation

InMed Pharmaceuticals Announces Preclinical Success of INM-901 in Reducing Alzheimer's-Related Inflammation